ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

Our Sponsors

Sponsor of the BAPA CE event

Pharmaceutical News

  • Roche opens access to pathology imaging tools to improve patient care
    on September 17, 2021 at 8:00 am

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the introduction of the Roche Digital Pathology Open Environment that allows software developers to easily integrate their image analysis tools for tumour tissue with Roche's uPath enterprise software, an application for pathologist workflow. This open environment allows for the secure exchange and flow of data so that pathologists can access advanced algorithms from third parties alongside Roche's menu of artificial intelligence-based image analysis tools.

  • COVID-19 nasal vaccine candidate effective at preventing disease transmission
    on September 16, 2021 at 8:00 am

    Breathe in, breathe out. That’s how easy it is for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in developing intramuscular vaccines against SARS-CoV- 2, such as the readily available Pfizer, Moderna and Johnson & Johnson vaccines, nothing yet - like a nasal vaccine - has been approved to provide mucosal immunity in the nose, the first barrier against the virus before it travels down to the lungs.

  • FDA advances data, IT modernization efforts with new office of digital transformation
    on September 15, 2021 at 8:00 am

    Today, the U.S. Food and Drug Administration announced the reorganization of the agency's information technology (IT), data management and cybersecurity functions into the new Office of Digital Transformation (ODT). The office has been realigned to report directly to the FDA commissioner, elevating the office and its functions to agency-level.

  • How a plant virus could protect and save your lungs from metastatic cancer
    on September 14, 2021 at 8:00 am

    Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a new treatment that could keep metastatic cancers at bay from the lungs. The treatment not only slowed tumor growth in the lungs of mice with either metastatic breast cancer or melanoma, it also prevented or drastically minimized the spread of these cancers to the lungs of healthy mice that were challenged with the disease.

  • Scientific evidence to date on COVID-19 vaccine efficacy does not support boosters for general population
    on September 13, 2021 at 8:00 am

    An expert review by an international group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe COVID is so high that booster doses for the general population are not appropriate at this stage in the pandemic. The review, published in The Lancet, summarises the currently available evidence from randomised controlled trials and observational studies published in peer-reviewed journals and pre-print servers.